Company: CERO
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-044335
Chunk: 65

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1
Chunk 65
---
,461  
     8.7%
  
    Loss from operations 
     (4,950,531) 
     (4,552,070) 
     (398,461) 
     8.7%

    Other income (expense): 

    Gain from settlement of liabilities with vendor 
     -  
     141,888  
     (141,888) 
     100.0%
  
    Change in fair value of derivative liabilities and earnout liabilities 
     -  
     2,120,117  
     (2,120,117) 
     (100.0)%
  
    Share-based inducement expense 
     (156,250) 
     -  
     (156,250) 
     (100.0)%
  
    Interest income (expense), net 
     850  
     (9,629) 
     10,479  
     108.8%
  
    Total other income (expense), net 
     (155,400) 
     2,252,376  
     (2,407,776) 
     (100.0)%

    Net loss 
     (5,105,931) 
     (2,299,694) 
     (2,806,237) 
     122.0%
  
    Deemed dividend on Series A, B and C Preferred Stock 
     (264,144) 
     -  
     (264,144) 
     100%
  
    Deemed dividend related to Series C Common Warrants 
     (84,083) 
     -  
     (84,083) 
     100%
  
    Net loss attributable to common stockholders 
    $(5,454,158) 
    $(2,299,694) 
    $(3,154,464) 
     137.2%

34

Research and Development Expenses

Research and development
expenses were $2.9 million for the three months ended March 31, 2025 as compared to $1.7 million for the three months ended March 31,
2024, reflecting an increase of $1.2 million. The increase was primarily attributable to an increase in clinal expenses of approximately
$1.3 million and an increase in scientific consulting fees of $0.4 million.